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Introduction 
 
Radiotherapy is an integral component of a multimodality treatment approach in head and neck (HN) cancer
 1
. 
Previous interest has primarily focused on tumour radiocurability but a shift towards cancer survivorship in 
recent years has seen growing interest in understanding radiation-induced complications in normal tissues 
2, 3
. 
Irradiated patients demonstrate variable normal tissue responses to radiotherapy despite apparently uniform 
treatments 
4
. While some of this may be due to stochastic effects, evidence supports the influence of 
deterministic variations in radioresponsiveness 
5
. Evidence of genetic and protein polymorphism underlying 
inter-individual differences in adverse responses of normal tissues to radiation is rapidly increasing 
6,7
. 
Unsurprisingly, much work has focused on the role of single nucleotide polymorphism (SNP) because it is the 
most common cause of the differences observed in DNA sequence among individuals 
8
.   
 
Many HN cancer patients achieve survivorship at the cost of treatment complications occurring in normal 
tissues. The ability to predict a predisposition for severe radiotherapy-induced adverse effects in normal 
tissues could potentially aid treatment decision-making, particularly in those with ‘intermediate risk’ disease 
9,10
. Avoiding or reducing radiation in these patients could lessen the likelihood of radiotoxicity-related 
morbidities and may also potentially reduce the burden of healthcare costs incurred for the supportive care 
required for these conditions. 
 
Genetic association studies (GAS) have been employed to identify causal functional SNPs in normal tissue 
radiotoxicity 
8
. Most genetic association studies have relied on the candidate gene approach (CGA), where 
postulated causal genes in radiobiological processes were selected for evaluation of associations. The genome-
wide approach (GWA) is an alternative method, where the entire genome is screened for significantly altered 
allele frequencies based on the linkage disequilibrium concept. Irrespective of the approach chosen, 
methodological considerations in GAS of radiotoxicity are critical to enable reliable interpretation of study 
findings, especially if these findings are to be translated into biomarkers of oncological treatment 
5,11
.  
 
Due to the lack of critical literature review on the association of SNPs with the occurrence of HN radiotoxicity 
normal tissues, we undertook the first systematic review in this subject based on the PRISMA statement 
12
, to 
gain a perspective of current knowledge as a basis to chart further work in this area. The specific aims are to 
(a) evaluate the reported relationship between genetic variants and adverse radiotherapy effects in HN cancer 
and (b) address the possibility of undertaking a meta-analysis of the genetic risk of various SNP in predicting 
HN radiotoxicity. 
 
Methods 
 
Research question 
Is there an association between gene polymorphisms and the occurrence of HN radiotoxicity?  
 
Definitions 
Radioresponsiveness is defined as the clinical features associated with the response to radiotherapy. 
‘Radiotoxicity’ is the temporary or permanent adverse changes/effects in normal tissue and/or related 
symptoms resulting from radiotherapy. ‘Radiosensitivity’ is the sensitivity of cells to irradiation in vitro, 
which is usually indicated by the surviving fraction at 2 Gy or by the parameters of the linear-quadratic or 
multitarget equations 
13,14
. This systematic review only considers normal tissue radiotoxicity and also in 
instances where the published study refers to this condition as ‘clinical radiosensitivity’.  
 
Search strategy   
A literature search of PubMed, Embase (1950-February 2012) and the Cochrane Reviews (to February 2012) 
was undertaken using various combinations of keywords and MeSH terms related to the subject. Searches 
were limited to human studies and the English language. The detailed search strategy used is available in 
supplementary information. Additionally, potential articles were also screened from the citation lists of 
retrieved articles and identified from expert source.  
 
Inclusion criteria  
(i) All prospective, cross-sectional and retrospective studies reporting on adverse effects involving 
radiotherapy in HN cancer with genetic polymorphism.  
(ii) Studies with sufficient data for estimating odds ratio (OR) and 95% confidence interval (95% CI). 
 
Exclusion criteria 
(i) Studies evaluating radiotoxicity in thyroid, oesophageal and other non-HN cancers.  
(ii) Eligible studies that provided insufficient information.  
(iii) Studies of cellular radiosensitivity derived from HN tumour and/or normal cell lines or animal studies.  
 
Study selection   
The list of retrieved articles was examined. Duplicates and obviously unrelated articles were eliminated.  
Abstracts of remaining articles were examined to determine if the full-text article should be obtained.  
 
Data extraction   
Relevant data were extracted from all eligible publications by one author using a standardized data extraction 
form. The following items were collected: author, year of publication, country of origin, ethnicity, type of 
study, type of radiotoxicity, total number of cases and controls, and confounding/covariates. Treatment and 
genotype distributions were also extracted. 
 
Types of outcome and measurement   
(i) Clinical endpoints of acute HN radiotoxicity e.g., mucositis, dysphagia, dermatitis.  
(ii) Clinical endpoints of late HN radiotoxicity e.g., subcutaneous fibrosis, osteoradionecrosis (ORN). 
(iii) Surrogate markers of HN radiotoxicity e.g., dependence on enteral tube feeding for dysphagia.  
 
Methodological quality assessment  
All eligible publications were subjected to methodological quality assessment based on the STrengthening the 
REporting of Genetic Association studies (STREGA) recommendations on reporting of genetic association 
studies 
15
.   
 Data synthesis    
Meta-analysis was not performed due to the substantial clinical heterogeneity of the data in the included 
studies. 
 
Results  
 
The search found 692 articles (Figure 1). After excluding 652 articles (12 duplicates; 640 unrelated and/or not 
GAS), 40 abstracts were considered. A further 29 abstracts were excluded based on the exclusion criteria and 
11 full text articles were retrieved.  On examining the full text articles, 5 articles were excluded based on 
exclusion criteria. One article was sourced through expert knowledge resulting in the final total of 7 articles 
eligible for further evaluation (Table 1).   
 
Results of the STREGA statement assessment are available as supplementary material. All HN radiotoxicity 
studies were first reports, declared the limitation of a small sample size and stated the need for validation in 
replication studies. Only 2 from 7 studies were undertaken prospectively. The number of patients included per 
study ranged from 32-140. There were 5/7 case-control and 2/7 cohort studies. Only three studies evaluated 
one primary site exclusively (oropharynx, 1; nasopharynx, 2). The mean age at treatment or diagnosis ranged 
from 50-61 years. Multimodality treatment was used in all studies (Table 2). A single ethnic group was 
considered in 3/7 studies involving Arab 
18,21
 and white American (non-Hispanic) 
22
 ancestries. Potentially 
confounding patient- and treatment-related factors were variably considered in all studies.  Genotyping 
technique was described adequately in all studies but internal validation was not reported. Univariate analysis 
was performed in 3/7 studies 
17,20,22
 and when significant factors were identified, 1/3 study performed 
multivariate analysis 
22
. The issue of population stratification was considered in three studies by using the 
Hardy-Weinberg equation 
16,17,22
, estimation of genotype frequency from a sample of 50 volunteers of similar 
age and gender 
21
 and consideration of allele frequency relating to the particular ethnic group 
22
.  
 
The clinical endpoints evaluated were acute mucositis, acute dysphagia, acute dermatitis/erythema, 
subcutaneous fibrosis and osteoradionecrosis. These were graded using the Common Terminology Criteria for 
Adverse Events, CTCAE 
23
 (3 studies) and the Radiotherapy Oncology Group/European Organization for 
Research and Treatment of Cancer, RTOG/EORTC 
24
 (2 studies).  Gastrostomy tube dependence was used as 
a clinical surrogate marker of radiation-induced dysphagia in one study 
22
.  Eleven polymorphisms in 8 genes 
were evaluated for association with acute radiotoxicity endpoints, and 6 polymorphisms in 4 genes were 
evaluated for late radiotoxicity endpoints (Table 2).   
 
Acute mucositis:  Three studies 
16,19,20
 evaluated this endpoint, consisting of two case-control studies, 
where severe acute mucositis (CTCAE, ≥ G2) was controlled against grades 0 or 1 16,20 and one cohort study of 
patients demonstrating various RTOG grades of acute mucositis 
19
. Cumulatively, there were 225 patients of 
various HN cancer subsites. IMRT (range mean tumour dose, 62-70 Gy; fractionated) was administered in 
three studies 
16,19,20
.  Chemotherapy was used variably in all studies. Cisplatin alone was used in 2 studies 
16,20
 
while a platinum-derived agent was used in multiagent combination protocol in 1 study 
19
 (Table 2). The 
impact of chemotherapy was considered in all three studies by univariate and/or multivariate analyses. The 
risk of severe acute mucositis (≥ G2) was associated with the G allele of XRCC1 (c.1196 A > G) in patients 
treated with both radiotherapy alone and chemoradiotherapy (OR, 4.02; p = 0.025; CI=1.16–13.90) 18 (Table 
4). Other assayed variants of DNA repair genes 
16,20
 and TGFβ1 19 were not associated with severe acute 
mucositis (Table 4). 
 
Acute dysphagia and acute dermatitis:  Two case-control studies 
16,20
 evaluated these endpoints. IMRT was 
administered in all patients in one study 
20
 while the other study had an undisclosed proportion receiving 
IMRT with SIB 
16
. While the mean tumour dose administered ranged between 62-70 Gy, attempts were made 
in both studies to provide a more accurate dose parameter in relation to the clinical endpoint. Both studies also 
considered the impact of chemotherapy using chi-squared test. Severe acute dysphagia (CTCAE, ≥ G2) was 
associated with the T allele in XRCC3 (722 C>T; OR=3.2; p=0.07) and the G allele in XRCC6 (1310 C>G; 
OR=4.08; p=0.014) and severe acute dermatitis (CTCAE, ≥ G2) was associated with the T allele of RAD51 
(3392 G>T; OR= 2.02; p = 0.216) 
20
.  
 Tube dependence >180 days:  Tube dependence >180 days as a surrogate marker of persistent dysphagia 
from radiotoxicity 
22
. This prospective study consisted of a homogenous cohort of American white, non-
Hispanics with oropharyngeal cancers treated by radiotherapy (with concomitant boost fractionation, 75/110 
cases) and chemotherapy (57/110 cases). Variants of ERCC4 gene (T2505C and G1244A) were evaluated 
against tube dependence >180 days. The C allele of ERCC4 T2505C SNP was found to significantly reduce 
the requirement of long-term gastrostomy tube placement in irradiated and chemo-irradiated patients. 
Following adjustment for significant factors on univariate analysis, the adjusted OR was 0.20 (95% CI, 0.06–
0.67).     
 
Subcutaneous skin fibrosis:  Two case-control retrospective studies 
18,21
 from the same centre evaluated 
subcutaneous fibrosis in a single ethnic group (Arab) with nasopharyngeal carcinoma treated using 3D 
radiotherapy (total neck dose, 66-70 Gy; fractionated) with chemotherapy employed in locally advanced 
diseases. Association between the risk of severe grade subcutaneous fibrosis with variants of TGFβ1 (-509 
C>T), XRCC1 (1196 A > G), XRCC3 (722 C>T) and mitochondrial DNA (mtDNA) were evaluated. No 
significant association was found between the risk of severe subcutaneous skin fibrosis with both XRCC3 and 
TGFβ1 18. However, the G allele of XRCC1 (1196 A > G) was associated with a lower grade of subcutaneous 
fibrosis (OR 0.30, 95% CI: 0.10–0.89, P = 0.02), suggesting that wild-types were the risk alleles 18.  
 
The possible association between mtDNA coding for mitochondrial respiratory activity with subcutaneous 
fibrosis was investigated 
21
. This study found a significantly higher number of nonsynonymous genetic 
variations in the severe fibrosis group (RTOG, ≥ G2) as compared with the control (G0-G1) groups (p=0.003). 
The nonsynonymous A10398G variation in the NADH dehydrogenase subunit 3 gene was significantly 
associated with fibrotic reaction (p=0.01). Radiosensitive patients had a 7-fold (95% CI, 1.16-51.65) higher 
risk of developing moderate to severe fibrosis (RTOG, ≥ G2) postradiotherapy. 
 
Osteoradionecrosis: The risk of developing ORN with TGFβ1 (-509 C>T) variant was evaluated in a 
multicenter, retrospective case-control study (ncase vs ncontrol: 39 vs 101) with heterogeneous diagnoses and 
treatment regime (total radiotherapy dose, 50-65 Gy; fractionated with 2/39 cases of brachytherapy; 
chemotherapy given in some) 
17
. Although univariate analyses of covariants were performed, the potential 
confounding factor of pre-extraction prophylactic measures, was not considered. ORN was found significantly 
associated with the T allele of TGFβ1-509 C>T polymorphism (OR, 4.2; 95% CI, 1.7-10.9), while the CC 
genotype was significantly associated with post-extraction related ORN. The positive and negative 
associations are summarized in Tables 3 and 4, respectively.  
 
Discussion 
 
Overall, this review found only a limited number (n=7) of normal HN tissue radiotoxicity GAS in comparison 
to the plethora of studies in other cancers 
6
. Due to case heterogeneity, a meta-analysis was not undertaken. All 
studies used the CGA method in cohort and case-control studies with small numbers of subjects, which are 
often characteristic of exploratory research phase. Therefore, the results only offer, at best, hypothesis-
generating findings needing validation in replication studies before any significant conclusions can be made. 
Bearing this caution in mind, the positive associations reported in these studies, and their biological pathways, 
were represented diagrammatically in Figure 2.  
 
The DNA damage response is essential for the maintenance of genomic integrity following irradiation and 
consists of specific DNA repair pathways that are initiated based on the type of DNA damage present 
25
. 
Double-strand DNA breaks occur frequently following irradiation and are repaired via homologous 
recombinant repair (HRR) and/or non-homologous end joining repair (NHEJ) 
25
. Non-end joining repair 
(NER) is rarely utilized in radiation-induced DNA damage although it is influential in the repair of DNA 
adducts induced by platinum chemotherapy and where irradiation occurs in the presence of hypoxia 
26
. DNA 
damage response genes were evaluated in 4/7 HN cancer studies based on the hypothesis that SNPs in these 
genes may alter the cellular capacity, particularly of cells showing high turnover, to repair sublethal damage 
following irradiation resulting in a more severe reaction. Unsurprisingly, these genes have been evaluated 
predominantly in acute HN radiotoxicity endpoints (3/4 studies) where variants of genes of the HRR pathway 
i.e. XRCC2, XRCC3 and RAD-51 paralogues 
27
 were found positively associated with acute mucositis 
16,20
. 
The significant association of XRCC6 gene variants with severe dysphagia 
20 
may be due to the role of its gene 
product, Ku, as a double-strand DNA break sensor in NHEJ repair 
28
. The ERCC1-XPF-ERCC4 complex 
performs a critical incision step in NER, and is also involved in the repair of DNA interstrand crosslinks 
29
. 
This may be the underlying cause of the C-allele ERCC4 T2505C being significantly associated with a 
reduction in requiring long-term gastrostomy tube placement in irradiated and chemo-irradiated patients 
24
.  
 
Radiation-induced fibrosis, a late radiotoxicity response, results from dysregulation of inflammation and 
regeneration. TGFβ1 retains a central role through its activation of fibroblasts into myofibroblasts 30. Once 
activated, myofibroblasts within irradiated tissues become unregulated to produce abundant collagen types I 
and III, which are the hallmarks of fibrosis. TGFβ1 also mediates various other biological pathways including 
angiogenesis 
31
 and bone formation 
32,33
. However, it is the role of TGFβ1 in radiation-induced fibrosis that 
provides the rationale for evaluating its genetic polymorphisms in radiotoxicities of normal HN soft and hard 
tissues 
17-19
 and led to the observations that the T-allele of TGFβ1 -509 C>T was significantly associated with 
ORN while the CC genotype of the -509 C>T was found significantly associated with ORN related to post-
radiation extraction 
17
 (Table 3).   In addition, the T allele of TGFβ1 -509 C>T was associated with a lower 
grade of skin fibrosis, suggesting that the wild-type of this allele was possibly related with late subcutaneous 
fibrosis in the Arab ethnic group 
18
.   
 
Radiation-generated reactive oxygen radicals (ROS) cause critical imbalances in cellular redox state, leading 
to significant cellular damage from oxidative stress 
34,35
. The mtDNA codes for components of the 
mitochondrial electron transport machinery, including NADH dehydrogenase, an energy-transducing enzyme 
34
. mtDNA variants may impair energy conversion and promote tissue accumulation of ROS. Nonsynonymous 
A10398G variation in the NADH dehydrogenase subunit 3 gene was significantly associated with fibrotic 
reaction (p=0.01) 
23
. No associations were identified between GSTP1 a peptide anti-oxidant that prevents 
ROS-induced metabolic oxidative stress, with HN radiotoxicity 
16
. Unfortunately, the oxidative metabolism 
pathway-related genes have not been evaluated more extensively in HN radiotoxicity studies despite the 
influence of radiation-induced ROS in multiple biological pathways including DNA damage repair, radiation-
induced fibrosis and chronic inflammatory responses 
30,34,35
.  
 With CGA, the selection and prioritization of candidate genes 
36
 directly impacts upon the results obtained, 
particularly in late radiotoxicity, where thought must be given to other genes that influence biological 
processes beyond cell survival 
37
. Multiple biological processes are engaged in normal tissues following 
irradiation 
30,34,35
, culminating in a particular clinical radiotoxicity phenotype. Accordingly, multiple risk SNPs 
could contribute towards this phenomenon 
38
, including SNPs in biological pathways that have not been 
previously deduced. Furthermore, site-specific biological responses may occur in different tissue-types due to 
the unique tissue constituent and its interaction with the immediate environment. A compendium of site-
specific factors and particular SNPs are associated with normal tissue radiotoxicity in lung 
39
, breast 
40
 and 
prostate 
41,42
 cancers, suggesting the possible influence of site-specific elements on selected SNPs in these 
circumstances. The incomplete understanding of mechanisms responsible for many complex traits (including 
radioresponsiveness) means that biological candidacy is inevitably speculative and could account for why this 
approach has so far yielded disappointing results in many common complex traits evaluated 
43,44
. Thus, a move 
towards GWA in normal tissue radiotoxicity GAS is advocated 
6,8,45
. To date, only one such study undertaken 
in a post-radiation prostate cancer cohort has been published, where GWA was used to evaluate the 
association of SNP with erectile dysfunction in African-American men 
46
.    
 
Common methodological issues in GAS influence both CGA and GWA with sample size being a major 
determinant of quality. Studies with a small sample size, e.g. the HN studies reviewed here, are frequently 
under-powered to detect a correct result and also run the risk of over-estimating the effect size when a positive 
result is obtained. With the remote chance of finding common genes with significant effects, studies must be 
powered to detect variants that are either common but have low relative risk or variants that are rare but with 
higher relative risk, which entails massive samples sizes in the order of thousands 
6,43
. Multicenter studies may 
overcome a small sample size problem by case pooling and this should be aimed for, particularly when 
replication studies are considered. 
 
A case-control design is the mainstay of GAS because it allows comparison between two groups that are 
expected to differ in their SNPs prevalence 
43
. In 5/7 HN radiotoxicity case-control studies reviewed, controls 
were obtained from a larger HN cancer cohort, where the control group generally consisted of patients who 
developed comparatively milder grades of toxicity (3/5 studies) or those that did not exhibit the toxicity (2/5 
studies). Defining the phenotype (i.e. radiotoxicity endpoint) is a fundamental methodological issue in 
radioresponsiveness since all irradiated patients are affected to some degree. Scoring systems for adverse 
events can help with phenotypic characterization 
6
. Established radiation-specific scoring systems include the 
RTOG/EORTC classification 
24
 and the LENT/SOMA scale 
47,48
. The CTCAE, which incorporates 
chemotherapy-related toxicities with RTOG/EORTC classifications 
23
, is increasingly used. However, its 
reliability could be undermined by dependence upon the clinician’s subjective interpretation of the severity of 
toxicity present 
49
. This may introduce the error of misclassification. Alternatively, distinct clinical endpoints 
of severe HN radiotoxicity can be used instead e.g., ORN, trismus and proximal oesophageal strictures. These 
clinical endpoints provide a more objective measure of radiotoxicity because of diagnostic unambiguity and in 
some instances, the prospect of quantitative assessment. This approach is also valuable when case pooling is 
considered in multicenter studies, where phenotype definition can be problematic when different scoring 
systems are used in different centres 
40
. One HN study has used this approach in choosing ORN 
17
. Other 
possible endpoints that may be considered in future HN radiotoxicity studies include imaging-based 
quantification of salivary gland function 
50,51
 and endoscopically-defined oesophageal strictures 
52-54
.  
 
Establishing uniformity within case and/or control group is essential to reduce the confounding effects of other 
factors that may contribute towards HN radiotoxicity. Heterogeneity within case and/or control group is an 
overwhelming problem highlighted in this review, mainly due to multimodality treatment and also variations 
in treatment protocols. Patient-related factors could introduce heterogeneity 
39,40
. Patient-related factors were 
considered variably in all studies evaluated in this review (Table 1). When it might not be possible to control 
for all these factors, employing multivariate statistical analysis could determine the level of significance of 
potentially confounding factors 
43
.  
 
Radiation dosimetry and dose-volume differences can directly influence severity of radiotoxicity 
5
. This 
problem may be addressed by homogenising radiation dose-volume parameters in critical areas (e.g. bone, 
pharyngeal muscle, skin and oral cavity mucosa) 
52-54
. This is increasingly considered in radiotoxicity GAS in 
other cancers 
43,55,56
. In this review, one study determined homogenized doses based on the dose-volume 
histogram 
20
 while another study used biologically effective dose (BED) values 
16
. BED accounts for the 
impact of radiation delivery and tissue tolerance to the biological effects observed 
57
 and is particularly used in 
other radiotoxicity GAS with fractionation protocols 
4, 58-62
.  
 
Many HN cancer patients undergo surgery, but it is impossible to standardize the surgical procedures received 
by individual patients. Clinical endpoints common to surgery and radiotherapy e.g., trismus, esophageal 
strictures and skin fibrosis/scarring, should be quantified at the completion of one treatment modality before 
the addition of another. Recording of post-surgical morbidity at a specified time point e.g., 6 weeks post-
surgery or 1 week pre-radiotherapy using standardized, valid and reliable definitions is fundamental to 
accurate measurement and monitoring of surgical adverse events. There is need for considered research and 
consensus in this area before it is possible to fully appreciate the range and degree of toxicity experienced by 
multimodality-treated HN cancer patients.  
  
Genotyping methods were described adequately in the 7 assessed papers, but internal validation was not 
reported in any HN studies. This may reflect the small numbers of cases available. Future larger studies using 
GWA with high-throughput screening should be performed in accredited laboratories with standard operating 
protocols 
63
, considered as critical factors in the quality of GAS as assessed by STREGA 
15
. All the HN cancer 
papers reviewed provided OR which was calculated individually for various genotypes or combinations of 
genotypes. The OR is presented for heterozygotes, homozygotes and for the combined group of heterozygotes 
and homozygotes rather than genotype relative risk values. Future studies ought to consider utilizing genetic 
models e.g., as suggested by Andreassen and Alsner 
6
, which accounts for the relationship between allele 
frequency and relative risk for genetic variants associated with normal tissue radiotoxicity.  
 
Learning from the experiences of other cancer sites 
6,42
, future HN normal tissue radiotoxicity studies should 
focus on conducting well-designed pilot study and validating these findings in larger studies. A suggested 
model is a case-control study design with subjects of defined ancestry, who are recruited prospectively. 
Careful characterization of cases and controls that limits heterogeneity is paramount. Regarding approach, 
GWA is a preferable platform over CGA due to its unbiased approach to the genome. When using the CGA, 
judicious selection of SNPs, quality control of genotyping and astute statistical analyses can optimize their 
usefulness and information 
36
. 
 
Still, there is an opportunity in the present to undertake a robust GAS study using existing data. There is a 
potentially large repository of data available from various randomized control trials in HN cancer involving 
radiation and/or chemoradiation. These studies may provide a large sample size from case pooling with high-
quality documentation on treatment parameters, toxicity and potential comorbidities. Other cancer sites have 
already moved towards multi-trial case pooling for validation of normal tissue radiotoxicity GAS, where 92 
SNPs from 46 genes were evaluated in 1613 patients with breast and prostate cancers recently 
63
. The 
amalgamation of trial data in HN cancer has started with the evaluation of the late complications in combined 
RTOG studies 
64
 and analyzing similarly accrued data in GAS of normal tissue radiotoxicity seems the logical 
next step forward.  
 
Another consideration is the incorporation of GAS as part of on-going prospective HN cancer studies featuring 
tissue collection. In the United Kingdom, the Head and Neck 5000 study 
65
 may provide an excellent 
opportunity for a GAS for radioresponsiveness because of the expected large sample size, prospective 
recruitment and tissue banking. However, potential issues could stem from case heterogeneity due to 
variations in treatment received at different centers, the influence of ethnicity and perhaps the target of 5000 
patients may yet provide adequate power to show for statistical relation between individual SNPs and 
radiotoxicity.   
 
Conclusions 
 
The association of common SNPs in normal tissue radiotoxicity following HN cancer treatment remains 
unproven. This is due to a combination of methodological issues. Preliminary results from these studies 
suggest the association of certain SNPs in genes involved in DNA damage response and radiation-induced 
fibrosis in the development of acute and late radiotoxicity endpoints. These findings require validation through 
replication studies. Future HN radiotoxicity genetic association study design must incorporate critical 
methodological issues and technological improvements, including using GWA. However, there is an 
opportunity to make headway in the present through case pooling of existing clinical trial data, creating a 
larger sample size consisting of patients with well-characterized treatment and endpoints. Also, HN cancer 
clinical trials that are currently running should consider extending their toxicity evaluation to include genetic 
association studies. These avenues could increase the likelihood of finding useful biomarkers of treatment, and 
may provide new ways in approaching supportive care of HN cancer survivors in the future.    
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 Table legends: 
Table 1. Summary of eligible studies.       
Table 2: Summary of the treatment received (exposure), outcomes and genetic variants evaluated. 
Table 3. Studies reporting positive associations.   
Table 4. Negative associations obtained. 
 
Figure legends: 
Figure 1: Flow chart showing the literature search. 
Figure 2: Diagram showing summary of genetic variants showing association with radiotoxicity.
 
